AP2001002038A0 - Pharmaceutical uses of NAB1 and NAB2. - Google Patents

Pharmaceutical uses of NAB1 and NAB2.

Info

Publication number
AP2001002038A0
AP2001002038A0 APAP/P/2001/002038A AP2001002038A AP2001002038A0 AP 2001002038 A0 AP2001002038 A0 AP 2001002038A0 AP 2001002038 A AP2001002038 A AP 2001002038A AP 2001002038 A0 AP2001002038 A0 AP 2001002038A0
Authority
AP
ARIPO
Prior art keywords
nab1
nab2
pharmaceutical uses
therapyl
nabi2
Prior art date
Application number
APAP/P/2001/002038A
Inventor
Martin Braddock
Callum Jeffrey Campbell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP2001002038A0 publication Critical patent/AP2001002038A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the use, particularly in gene therapyl of an nabi or nabi2 polypeptide or a biologically active fragment thereof, and to nucleic acid molecules encoding such polypeptides, in the manufacture of a medicament for the treatment of cell proliferation disorders associated with wound healing in a mammal, including human
APAP/P/2001/002038A 1998-07-11 1999-07-09 Pharmaceutical uses of NAB1 and NAB2. AP2001002038A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Publications (1)

Publication Number Publication Date
AP2001002038A0 true AP2001002038A0 (en) 2001-03-31

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002038A AP2001002038A0 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of NAB1 and NAB2.

Country Status (22)

Country Link
EP (1) EP1097200A1 (en)
JP (1) JP2002520020A (en)
KR (1) KR20010071832A (en)
CN (1) CN1317045A (en)
AP (1) AP2001002038A0 (en)
AU (1) AU763713B2 (en)
BR (1) BR9912018A (en)
CA (1) CA2336805A1 (en)
EA (1) EA200100028A1 (en)
EE (1) EE200100020A (en)
HR (1) HRP20010025A2 (en)
HU (1) HUP0102835A3 (en)
ID (1) ID27742A (en)
IL (1) IL140533A0 (en)
IS (1) IS5788A (en)
NO (1) NO20010166L (en)
NZ (1) NZ509174A (en)
PL (1) PL345507A1 (en)
SK (1) SK382001A3 (en)
TR (1) TR200100622T2 (en)
WO (1) WO2000003014A1 (en)
YU (1) YU1901A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
ID27742A (en) 2001-04-26
CN1317045A (en) 2001-10-10
SK382001A3 (en) 2001-09-11
CA2336805A1 (en) 2000-01-20
PL345507A1 (en) 2001-12-17
NO20010166L (en) 2001-03-06
JP2002520020A (en) 2002-07-09
YU1901A (en) 2005-06-10
IS5788A (en) 2000-12-22
EP1097200A1 (en) 2001-05-09
AU763713B2 (en) 2003-07-31
WO2000003014A1 (en) 2000-01-20
NO20010166D0 (en) 2001-01-10
EA200100028A1 (en) 2001-08-27
AU4791499A (en) 2000-02-01
EE200100020A (en) 2002-06-17
HRP20010025A2 (en) 2001-12-31
NZ509174A (en) 2003-08-29
KR20010071832A (en) 2001-07-31
TR200100622T2 (en) 2001-10-22
HUP0102835A3 (en) 2003-09-29
HUP0102835A2 (en) 2001-11-28
BR9912018A (en) 2006-01-31
IL140533A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
Morizane et al. Antimicrobial peptides in the pathogenesis of psoriasis
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
ATE255128T1 (en) PEPTIDE-IMMITTING SUBSTANCES IN CANCER THERAPY
ATE451929T1 (en) PEPTIDES DERIVED FROM CASEIN AND THEIR APPLICATION FOR THERAPY
MXPA02002384A (en) Fibroblast growth factor like polypeptides.
EP2679235A3 (en) Peptides and related molecules that modulate nerve growth factor activity
NZ500657A (en) Interleukin-3 gene therapy for cancer
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
ATE209684T1 (en) DNA SEQUENCES FOR MATRIX METAL PROTEASES, THEIR PREPARATION AND USE
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
ATE281159T1 (en) USE OF AMINO ACID IN THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF INSULIN RESISTANCE
EP1114862A3 (en) Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances
AP2001002038A0 (en) Pharmaceutical uses of NAB1 and NAB2.
WO2003039591A3 (en) Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2000042166A3 (en) Methods and compositions for monitoring cellular processing of epitope-tagged beta-amyloid precursor protein
WO2003072126A3 (en) Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
KR100488038B1 (en) New bpc peptide salts with organo-protective activity the process for their preparation and their use in therapy
EP0905234A3 (en) Allelic variant of human STAT3
ATE230027T1 (en) HUMAN DNASE I VARIANTS
WO2002083060A3 (en) Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
ATE403434T1 (en) PEPTIDES FOR MODULATING CARTILAGE HOMEOSTASIS
CA2601208A1 (en) Method of preventing or treating type 1 diabetes by gene therapy with a secreted form of glutamic acid decarboxylase.